Advertisement

Topics

Kensey Nash Corporation Company Profile

19:50 EDT 21st September 2018 | BioPortfolio


News Articles [348 Associated News Articles listed on BioPortfolio]

[Comment] FGF-19 agonism for NASH: a short study of a long disease

Non-alcoholic steatohepatitis (NASH) has emerged as the most common cause of liver disease worldwide and is on a trajectory to become the most common indication for liver transplantation.1,2 Interest ...

Startup Terns Secures Three NASH Assets From Eli Lilly

The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three ...

Drs. Jonathan and Kenneth Nash Treat Gum Disease in Vicksburg, MS with Modern Laser Dentistry, Honor National Gum Care Month

VICKSBURG, MS (PRWEB) September 13, 2018 Nash Family Dentistry team, Drs. Jonathan Nash and Kenneth Nash, are honoring National Gum ...

NASH Cirrhosis: The Real NASH Epidemic

AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition

Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space...   

First International NASH Day is a Call to Action

The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease ...

The European Fight Against NASH, The Silent Liver Disease

Today is the First International NASH Day, and to mark the occasion, we bring you an update on Europe’s efforts to tackle this largely unrecognized liver disease that currently has no treatment and ...

Nonalcoholicsteatohepatitis (NASH) Pipeline Analysis – Forecast to 2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Nonalcoholicsteatohepatitis (NASH) Pipeline Analysis – Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering. Thi...

PubMed Articles [100 Associated PubMed Articles listed on BioPortfolio]

Nonalcoholic steatohepatitis in posttransplantation liver: Review article.

Nonalcoholic steatohepatitis (NASH) associated or not with cirrhosis is the third leading indication for liver transplantation (LT) around the world. After transplants, NASH has a high prevalence and ...

Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States.

Non-alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD). Our aim was to estimate the total economic burden of NASH and advanced NASH in the United Sta...

Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score.

Nonalcoholic steatohepatitis (NASH) is an important etiology of end-stage liver disease. Long-term effect of bariatric surgery in improvement of NASH is not clear.

Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) can advance, if untreated, to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and liver-related de...

A long-acting FGF21 alleviates hepatic steatosis and inflammation in NASH mice partly through an FGF21- adiponectin- IL17A axis.

NASH is the most severe form of NAFLD and is a serious public health problem around the world. There are currently no approved treatments for NASH. FGF21 has recently emerged as a promising drug candi...

Clinical Trials [159 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [204 Associated Companies listed on BioPortfolio]

Kensey Nash Corp.

Kensey Nash Corporation

Kensey Nash

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occlud...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

More Information about "Kensey Nash Corporation" on BioPortfolio

We have published hundreds of Kensey Nash Corporation news stories on BioPortfolio along with dozens of Kensey Nash Corporation Clinical Trials and PubMed Articles about Kensey Nash Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kensey Nash Corporation Companies in our database. You can also find out about relevant Kensey Nash Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record